[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dose-escalation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dose-escalation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100466035","fmiso-based-adaptive-radiotherapy-for-head-and-neck-cancer-100466035",false,"NCT05348486","FMISO-based Adaptive Radiotherapy for Head and Neck Cancer","FMISO-based Adaptive Radiotherapy for Head and Neck Cancer - a Prospective Multicenter Study","FARHEAD","Inclusion Criteria:\n\n* Pathologically proven new diagnosis of oropharyngeal p16 negative, or laryngeal, hypopharyngeal, oral cavity (independent of p16) squamous cell carcinoma of clinical stage III, IV confined to head and neck area\n* Evaluable tumor burden assessed by computed tomography scan or magnetic resonance imaging, based on RECIST (Response Evaluation Criteria in Solid Tumours) version 1.1\n* Eligibiity for definitive chemoradiation or hyperfractionated accelerated radiotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate kidney and liver function\n\nExclusion Criteria:\n\n* Prior surgical treatment - any surgery of primary tumor or involved nodes or prior surgical debulking apart from surgery with diagnostic intention (e.g. open biopsy if necessary)\n* Prior systemic therapy, targeted therapy, radiotherapy treatment for head and neck cancer\n* Cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or unknown primary head and neck cancer\n* Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis or any distant metastasis\n* Known active Hepatitis B or C\n* History of Human Immunodeficiency Virus (HIV)\n* History of a diagnosed and\u002For treated hematologic or primary solid tumor malignancy, unless in remission for at least 5 years prior to randomization\n* Previous allogeneic tissue\u002Fsolid organ transplant\n* Active infection requiring systemic therapy","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","Hypoxia occurs in about 80% of head and neck tumors. Based on experimental and clinical data, hypoxia is a useful parameter for pretherapeutic stratification. These radioresistant regions can be detected with FMISO PET\u002FCT. Moreover, hypoxic subvolumes of tumors can be evolving as target volumes for radiotherapy (\"dose painting\") in hypoxia imaging-based dose escalation.",[27,28,29,30],"Head and Neck Cancer","Hypoxia","FMISO","Dose Escalation",[27,28,32,33],"Radiotherapy","Dose escalation","RECRUITING","2025-04-16",{"date":37,"type":38},"2025-04-22","ACTUAL",{"date":40,"type":38},"2022-04-20",{"date":42,"type":21},"2030-06-30",{"name":44,"class":45},"University Hospital Olomouc","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":5},"100356363","salvage-hypofractionated-accelerated-versus-standard-radiotherapy-for-biochemical-failure-after-prostatectomy-100356363","NCT03920033","Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy","Comparison of Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy (SHARE Trial): a Prospective, Randomized Controlled, Open-label, Multi Center, Superiority Study","SHARE","Inclusion Criteria:\n\n* Pathologically confirmed intermediate- or high-risk prostate cancer\n* Biochemical recurrence after radical prostatectomy (Definition: Serial elevation of PSA over 0.2 ng\u002FmL and \\\u003C=1.0 ng\u002FmL)\n* ECOG performance status 0-1\n* Appropriate values of blood tests within 6 months after enrollment Absolute neutrophil count (ANC) ≥ 1500 cells\u002Fmm3 Platelets ≥ 50,000 cells\u002Fmm3 Hemoglobin ≥ 8.0 g\u002Fdl\n* Appropriate values of kidney function within 6 months after enrollment Creatinine \\\u003C 2.0 ng\u002FdL\n* Appropriate values of liver function within 6 months after enrollment total bilirubin \\\u003C 1.5 X maximum normal value alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5 X maximum normal value\n\nExclusion Criteria:\n\n* Clinically gross recurrent tumor\n* Presence of distant metastasis\n* Presence of pelvic LN metastasis\n* History of pelvic irradiation\n* History of cryotherapy or brachytherapy for prostate cancer\n* Double primary cancer other than skin\u002Fthyroid cancer\n* Combined serious morbidity","MALE","20 Years",{"count":58,"type":21},288,[24],"Patients with a biochemical recurrence after radical prostatectomy for moderate- or high- risk prostate cancer are randomly assigned to hypofractionated, accelerated high dose radiation therapy group (65 Gy, 26 fractions) and a control group of standard treatment group (66 Gy, 33 fractions). The criteria for stratification at randomization include 1) risk groups, 2) androgen deprivation therapy, and 3) PSA before salvage radiation therapy, which affect biochemical recurrence.\n\nIt is expected that hypofractionated, accelerated high dose radiation therapy will have a superiority in terms of biochemical control to conventional radiation therapy, and the present study would like to confirm this. In addition, we aimed to evaluate and compare the toxicity and quality of life index of two radiation therapy regimens.",[62,63,64,65,30,66,67,68],"Prostate Cancer","Biochemical Recurrence","Radiation","Hypofractionation","Survival","Radiation Toxicity","Quality of Life","2021-01-15",{"date":71,"type":38},"2021-01-20",{"date":73,"type":38},"2019-05-01",{"date":75,"type":21},"2027-01-01",{"name":77,"class":45},"Asan Medical Center"]